Skip to main content

Table 2 Patients’ treatments and follow-up

From: The prognostic value of 18F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients

Clinical Characteristics   Patients
Neoadjuvant chemotherapy Yes 35 (92.1%)
No 3 (7.9%)
Surgery Yes 38 (100%)
No 0 (0%)
Post-operative chemotherapy Yes 37 (97.4%)
No 1 (2.6%)
Endpoint events Dead 2 (5.3%)
Recurrence or progression 17 (44.7%)
Disease free 19 (50.0%)